News

Video

Behind the mechanism of action of brimonidine tartrate ophthalmic solution

Key Takeaways

  • Brimonidine tartrate targets alpha two receptors, reducing side effects and rebound redness compared to traditional vasoconstrictors.
  • A study of 50 million units over four years showed minimal rebound redness and ineffectiveness with Lumify.
SHOW MORE

At the Tear Film and Ocular Surface meeting in Venice, Melissa Toyos shares findings on the mechanism of action of brimonidine tartrate.

At the Tear Film and Ocular Surface: Basic Science and Clinical Relevance meeting in Venice, Italy, Melissa Toyos, MD, presented her insights on ocular vascular constrictors, specifically focusing on brimonidine tartrate ophthalmic solution (Lumify; Bausch + Lomb). This presentation sheds light on the safety and efficacy of this innovative product, offering eye care providers essential information for patient care.

Toyos emphasized the widespread availability of over-the-counter vasoconstrictors, noting that while they provide quick relief from redness, their safety varies significantly. The key takeaway from her research, which involved a comprehensive analysis of 50 million units over four years, was the specific mechanism of action of Lumify. Unlike traditional redness relievers that act on alpha one adrenergic receptors—which constrict arteries and can compromise ocular nutrition—brimonidine selectively targets alpha two receptors. This distinction is crucial, as it minimizes potential side effects and reduces the risk of rebound redness, a common problem with conventional products.

One of the standout findings from Toyos’s study is that the occurrence of rebound redness with Lumify was extremely low, with only nine reported cases among the large sample size. This significantly lowers the risk of dependence that can occur with other redness relievers, which often lead to a cycle of overuse and increasing dissatisfaction. The study reported an almost negligible rate of ineffectiveness, underscoring Lumify’s safety profile.

Toyos also addressed the impact of brimonidine on the ocular surface. While the study primarily focused on self-reported adverse events, she noted the favorable vehicle composition of Lumify, which includes glycerin, making it comfortable for patients. The small active ingredient concentration further enhances its tolerability, setting it apart from other options.

In summary, Toyos encouraged eye care providers to embrace Lumify as a scientifically-backed option for managing ocular redness. She praised Bausch + Lomb’s commitment to research and safety, reinforcing that eye care professionals can confidently recommend Lumify to their patients without the fear of dependency or adverse effects associated with traditional vasoconstrictors. This innovative approach offers a promising solution for patients seeking relief from redness while maintaining the health of their ocular surface.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.